ANTHOS THERAPEUTICS
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases. The company was founded by a world-class executive team with extensive experience in the development and commercialization of CVM disease therapies.
ANTHOS THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.anthostherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
617-430-6940
Total Funding:
250 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Arpeggio Bio
Arpeggio builds technology to watch and learn how drugs work.
Astria Therapeutics
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Derm-Biome Pharmaceuticals, Inc
A biopharmaceutical company focused on inflammatory skin diseases and skin cancer.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
VelaVigo
VelaVigo is a start-up company engaged in macromolecular biopharmaceutical.
Current Employees Featured
William Meury CEO @ Anthos Therapeutics
CEO
2024-04-01
John Glasspool CEO & President @ Anthos Therapeutics
CEO & President
2019-02-01
David McIntyre Chief Financial Officer @ Anthos Therapeutics
Chief Financial Officer
2021-11-01
Jonathan Freeman COO @ Anthos Therapeutics
COO
2019-02-01
Drew Young Chief Commercial Officer and Head of Patient Experience @ Anthos Therapeutics
Chief Commercial Officer and Head of Patient Experience
2022-04-01
Founder
Investors List
Blackstone Life Sciences
Blackstone Life Sciences investment in Series A - Anthos Therapeutics
Novartis
Novartis investment in Series A - Anthos Therapeutics
Novo Seeds
Novo Seeds investment in Venture Round - Anthos Therapeutics
Key Employee Changes
Official Site Inspections
http://www.anthostherapeutics.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Anthos Therapeutics"
Home - Anthos Therapeutics
£¬šÀŒÔ¬ ÍÀq=Öyÿí-³ïøç‹mÇew ˜CRwK;^ïqOîÉÞS*$ž$b >F¥½ i_¾ŒA¸A h»--CÄÙd»?ªºuƒ¦@à@ðA È `€u«êÞ÷úu?¹%YcBùÛ û Ùƒ`ZˆR ...See details»
About - ANTHOS THERAPEUTICS
Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic options for the treatment of cardiovascular metabolic diseases, founded by Blackstone Life Sciences …See details»
Anthos Therapeutics Appoints Will Kane as President and Chief ...
CAMBRIDGE, MASS., October 31, 2024 – Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the …See details»
Anthos Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Www.anthostherapeutics.com. Startups | Holding Company | 2018 | Massachusetts, United States | 10-50 | www.anthostherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. ... The …See details»
Anthos Therapeutics - Crunchbase Company Profile & Funding
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases. The company was founded by a world-class executive …See details»
Anthos Therapeutics Company Profile | Management and
Www.anthostherapeutics.com Anthos Therapeutics Profile and History Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization …See details»
Anthos Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Anthos Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Anthos Therapeutics - Company Profile - Tracxn
Nov 5, 2024 Anthos Therapeutics - Developer of targeted antibodies to treat thrombotic diseases. Raised a total funding of $250M over 1 round from 5 investors. Founded by …See details»
Anthos Therapeutics - workinbiotech.com
Anthos is a clinical stage biopharmaceutical company based in Cambridge, MA that was launched in 2019 by Blackstone Life Sciences. They are focused on developing and validating …See details»
Anthos Therapeutics Company Overview, Contact Details
Feb 27, 2019 Anthos Therapeutics, Inc hired Will Kane as chief financial officer on Oct 31st '24. CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) - Anthos Therapeutics, Inc. …See details»
Anthos Therapeutics - LinkedIn
Anthos Therapeutics | 4,159 followers on LinkedIn. Anthos Therapeutics is a clinical-stage biopharma company developing innovative therapies for cardiovascular patients. | Anthos …See details»
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
Aug 28, 2024 CAMBRIDGE, Mass., – April 22, 2024 – Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded …See details»
Anthos Therapeutics - Overview, News & Similar companies
May 5, 2024 Anthos Therapeutics contact info: Phone number: (617) 430-6940 Website: www.anthostherapeutics.com What does Anthos Therapeutics do? Anthos Therapeutics is a …See details»
Anthos Therapeutics - VentureRadar
"Anthos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for high-risk cardiovascular patients.See details»
Anthos Therapeutics - Craft
Anthos Therapeutics is a biopharmaceutical company developing therapies for cardiovascular patients. It provides MAA868, an antibody directed at Factor XI and XIa, key components of …See details»
Press Room - Anthos Therapeutics
AZALEA-TIMI 71-A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in …See details»
Anthos Therapeutics Information - RocketReach
Anthostherapeutics.com; 1 732787XXXX; View Similar People. Related Companies Sigilon Therapeutics, Inc. 64 $11.4m Cerevel Therapeutics. 361 $63m FogPharma. 153 $5.5m Arbor …See details»
Anthos Therapeutics, Inc. (Anthos Therapeutics, Inc.) - 药物管线_专 …
Abstract Abelacimab is a fully human IgG1 monoclonal antibody that has dual activity against the inactive zymogen Factor XI (FXI) and the activated Factor XI (FXIa). Clinical trials for this …See details»
Science - Anthos Therapeutics
Over the past decade, efforts to develop safer antithrombotic strategies have largely focused on Factor XI. 5 Abelacimab is a novel, highly selective, fully human monoclonal antibody that …See details»
Anthos Therapeutics' novel Factor XI inhibitor abelacimab …
Aug 15, 2024 CAMBRIDGE, Mass., July 19, 2021 – Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic …See details»